JP2004504360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504360A5 JP2004504360A5 JP2002513505A JP2002513505A JP2004504360A5 JP 2004504360 A5 JP2004504360 A5 JP 2004504360A5 JP 2002513505 A JP2002513505 A JP 2002513505A JP 2002513505 A JP2002513505 A JP 2002513505A JP 2004504360 A5 JP2004504360 A5 JP 2004504360A5
- Authority
- JP
- Japan
- Prior art keywords
- tolyl
- ethoxy
- urea
- tert
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl Chemical group 0.000 description 12
- 239000004202 carbamide Substances 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000008187 granular material Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000001116 FEMA 4028 Substances 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 4
- 229960004853 betadex Drugs 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- FVSUYFWWFUVGRG-UHFFFAOYSA-N naphthalen-1-ylurea Chemical compound C1=CC=C2C(NC(=O)N)=CC=CC2=C1 FVSUYFWWFUVGRG-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22038700P | 2000-07-24 | 2000-07-24 | |
| PCT/US2001/021860 WO2002007772A2 (en) | 2000-07-24 | 2001-07-11 | Improved oral dosage formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004504360A JP2004504360A (ja) | 2004-02-12 |
| JP2004504360A5 true JP2004504360A5 (https=) | 2008-08-28 |
Family
ID=22823354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002513505A Pending JP2004504360A (ja) | 2000-07-24 | 2001-07-11 | １−（５−ｔｅｒｔ−ブチル−２−Ｐ−トリル−２Ｈ−ピラゾール−３−イル）−３−［４−（２−モルホリン−４−イル−エトキシ）−ナフタレン−１−イル］−ウレアの改良された経口製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6565880B2 (https=) |
| EP (1) | EP1305050A2 (https=) |
| JP (1) | JP2004504360A (https=) |
| CA (1) | CA2415131A1 (https=) |
| MX (1) | MXPA02012909A (https=) |
| WO (1) | WO2002007772A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858617B2 (en) | 1998-05-26 | 2005-02-22 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| WO2000025791A1 (en) | 1998-11-04 | 2000-05-11 | Smithkline Beecham Corporation | Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| AU1781601A (en) | 1999-11-23 | 2001-06-04 | Smithkline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| EP1233951B1 (en) | 1999-11-23 | 2005-06-01 | SmithKline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| ATE305787T1 (de) | 1999-11-23 | 2005-10-15 | Smithkline Beecham Corp | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren |
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| EP1709965A3 (en) | 2001-07-11 | 2006-12-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediate diseases |
| CA2454913A1 (en) * | 2001-08-20 | 2003-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin |
| EP1455791A1 (en) * | 2001-12-11 | 2004-09-15 | Boehringer Ingelheim Pharmaceuticals Inc. | Method for administering birb 796 bs |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| DE10223783A1 (de) * | 2002-05-29 | 2003-12-11 | Boehringer Ingelheim Pharma | Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers |
| US20040110755A1 (en) * | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
| EP1539121A4 (en) | 2002-08-29 | 2008-08-13 | Scios Inc | METHOD OF REQUESTING OSTEOGENESIS |
| WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| JP4689468B2 (ja) * | 2003-07-10 | 2011-05-25 | 協和発酵バイオ株式会社 | 錠剤およびその製造方法 |
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| US7244441B2 (en) | 2003-09-25 | 2007-07-17 | Scios, Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
| WO2005063715A1 (en) * | 2003-12-18 | 2005-07-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Polymorph of birb 796, a p38map kinase inhibitor |
| CN101026725B (zh) * | 2005-07-15 | 2010-09-29 | 索尼株式会社 | 再现设备及再现方法 |
| JP4251298B2 (ja) | 2005-07-15 | 2009-04-08 | ソニー株式会社 | 再生装置および再生方法、プログラム、プログラム格納媒体、データ、記録媒体、記録装置、および、記録媒体の製造方法 |
| MY150649A (en) | 2006-10-20 | 2014-02-14 | Icos Corp | Compositions of chk1 inhibitors |
| US20100016449A1 (en) * | 2006-12-21 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Formulations with Improved Bioavailability |
| EP3257862A1 (en) | 2016-06-16 | 2017-12-20 | ETH Zürich | Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464633A (en) * | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| ATE312823T1 (de) | 1999-07-09 | 2005-12-15 | Boehringer Ingelheim Pharma | Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen |
| US6254888B1 (en) * | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
-
2001
- 2001-07-11 US US09/902,822 patent/US6565880B2/en not_active Expired - Lifetime
- 2001-07-11 WO PCT/US2001/021860 patent/WO2002007772A2/en not_active Ceased
- 2001-07-11 CA CA002415131A patent/CA2415131A1/en not_active Abandoned
- 2001-07-11 MX MXPA02012909A patent/MXPA02012909A/es active IP Right Grant
- 2001-07-11 EP EP01984305A patent/EP1305050A2/en not_active Withdrawn
- 2001-07-11 JP JP2002513505A patent/JP2004504360A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004504360A5 (https=) | ||
| JP3881377B2 (ja) | 新規な製剤および方法 | |
| US5529783A (en) | Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan | |
| PT1124539E (pt) | Formulacao farmaceutica compreendendo omeprazole | |
| US5489436A (en) | Taste mask coatings for preparation of chewable pharmaceutical tablets | |
| IS2856B (is) | Lyfjablanda úr ómeprasól | |
| AU674175B2 (en) | Oral compositions containing 1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxyaldehyde-o- methyl-oxime | |
| DK0868910T3 (da) | Anvendelse af redispergerbare polymerpulvere eller polymergranulater som bindemidler til fremstilling af faste farmaceutiske dispergeringsformer | |
| KR20210002091A (ko) | 히프로멜로오스 아세트산에스테르 숙신산에스테르를 사용한 스프레이 드라이용 용액 및 고체 분산체의 제조 방법 | |
| JPH10511117A (ja) | 酸不安定性オメパラゾールを含有する新規組成物及びその製造方法 | |
| CA2211284A1 (en) | Multiple unit sustained release dosage form | |
| EP0277741A1 (en) | Spherical granules having core and their production | |
| AU587863B2 (en) | Vitamin-containing granules and production thereof | |
| HU198385B (en) | Process for producing peroral pharmaceutical compositions containing acid-sensitive benzimidazol derivatives for treating gastrointestinal illnesses | |
| NO870558L (no) | Fremgangsmaate for fremstilling av et langsomt frigivende farmasoeytisk preparat. | |
| AR065072A2 (es) | Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo | |
| JP2004504360A (ja) | １−（５−ｔｅｒｔ−ブチル−２−Ｐ−トリル−２Ｈ−ピラゾール−３−イル）−３−［４−（２−モルホリン−４−イル−エトキシ）−ナフタレン−１−イル］−ウレアの改良された経口製剤 | |
| JP2005516923A5 (https=) | ||
| AU7539098A (en) | Benzimidazole pharmaceutical composition and process of preparation | |
| JP2025182116A5 (https=) | ||
| CN1106837C (zh) | 碱化钾盐控释制剂 | |
| CS261791A3 (en) | Process for preparing preparations in the form of tablets or coated tablets containing light, heat and moisture sensitive active component having a monoclinic crystal structure | |
| CA2470609A1 (en) | Tableted oral pharmaceutical dosage form, with an enteric coating, containing a benzimidazole compound labile in an acid medium | |
| CA2136607C (en) | Pharmaceutical powder composition containing non-ionic cellulose ether derivative and a chitin-derived polymer | |
| AU776384B2 (en) | Stable galenic preparations comprising a benzimidazol and method for the production thereof |